These results showed that pre-treatment with rosiglitazone attenuates cisplatin-induced renal damage through the suppression of TNF-alpha overproduction and NF-kappaB activation.

These results suggest that OTC can be a potential therapeutic agent in cisplatin-induced renal injury through decreasing the ROS levels and activation of NF-kappaB.

No abstract

ity, where fluid is reabsorbed easily; (ii) greater omentum itself is able to absorb large amount of fluid; and (iii) after the marsupialisation, the greater omentum adheres to the renal surface and then gradually seals the damaged surface.

No abstract